-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the State Drug Administration approved the application for
the listing and registration of the 1.
2 class of Chinese medicine innovative drug Guangqiancao total flavone capsules.
The main ingredient of the drug is the total flavonoids extracted from Guangqian Herb, and the holder of the drug marketing authorization is Wuhan Guanggu Renfu Biopharmaceutical Co.
, Ltd.
the listing and registration of the 1.
2 class of Chinese medicine innovative drug Guangqiancao total flavone capsules.
The main ingredient of the drug is the total flavonoids extracted from Guangqian Herb, and the holder of the drug marketing authorization is Wuhan Guanggu Renfu Biopharmaceutical Co.
, Ltd.
The drug has carried out randomized, double-blind, placebo parallel control, multicenter clinical trials, and the results of clinical trials show that there is a statistical difference between the comparison with the placebo control group, which can be used for the treatment
of ureteral stones in patients with damp heat syndrome in traditional Chinese medicine.
of ureteral stones in patients with damp heat syndrome in traditional Chinese medicine.
The launch of this variety will provide new treatment options
for patients with clinically related diseases.
The drug supervision and administration department will strengthen the post-marketing supervision of the drug to protect the safety
of patients.
for patients with clinically related diseases.
The drug supervision and administration department will strengthen the post-marketing supervision of the drug to protect the safety
of patients.
Recently, the State Drug Administration approved the application for
the listing and registration of the 1.
2 class of Chinese medicine innovative drug Guangqiancao total flavone capsules.
The main ingredient of the drug is the total flavonoids extracted from Guangqian Herb, and the holder of the drug marketing authorization is Wuhan Guanggu Renfu Biopharmaceutical Co.
, Ltd.
the listing and registration of the 1.
2 class of Chinese medicine innovative drug Guangqiancao total flavone capsules.
The main ingredient of the drug is the total flavonoids extracted from Guangqian Herb, and the holder of the drug marketing authorization is Wuhan Guanggu Renfu Biopharmaceutical Co.
, Ltd.
The drug has carried out randomized, double-blind, placebo parallel control, multicenter clinical trials, and the results of clinical trials show that there is a statistical difference between the comparison with the placebo control group, which can be used for the treatment
of ureteral stones in patients with damp heat syndrome in traditional Chinese medicine.
TCMof ureteral stones in patients with damp heat syndrome in traditional Chinese medicine.
The launch of this variety will provide new treatment options
for patients with clinically related diseases.
The drug supervision and administration department will strengthen the post-marketing supervision of the drug to protect the safety
of patients.
Disease medicines and medicines for patients with clinically related diseases.
The drug supervision and administration department will strengthen the post-marketing supervision of the drug to protect the safety
of patients.
